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DMN, those with TGF-b CC/CT genotypes also had worseAssociation of transforming growth factor-beta (TGF-) T869C
renal function and increased risk for macroalbuminuria.(Leu 10Pro) gene polymorphisms with type 2 diabetic nephrop-
Conclusion. Our results suggest that TGF-b T869C (Leuathy in Chinese.
10Pro) gene polymorphism is associated with DMN in Chinese.Introduction. Transforming growth factor- (TGF-) is known
to play a pivotal role in the regulation of extracellular matrix
(ECM) accumulation. Since diabetic nephropathy (DMN) is char-
acterized by basement membrane thickening and mesangial Type 2 diabetic nephropathy (DMN) is an importantexpansion, control of ECM deposition is believed to be impor-
cause of end-stage renal failure (ESRF) worldwide. Intant in the pathogenesis of the disease. Recently, TGF-b T869C
Hong Kong, DMN leading to maintenance dialysis has(Leu 10Pro) gene polymorphism has been identified which may
be associated with circulating TGF- levels. increased from 17% 10 years ago to 30% in recent years
Methods. In order to examine the relationship between TGF- [1]. While the importance of metabolic and blood pres-
gene polymorphism with DMN in Chinese, we carried out a sure control in the pathogenesis of DMN is fully recog-case-control study, which recruited 123 Chinese type 2 diabetic
nized [2], the role of genetic factor is still poorly under-patients with an average duration of diabetes for 12 years. A
stood.total of 58 patients who developed DMN (micro- or macroalbu-
minuria, with or without renal impairment) were compared Diabetes-related complications are found to be more
with 65 diabetic patients without DMN despite similar duration common among Asians than Western populations even
of disease (normoalbuminuric and creatinine 120 mol/L). after correction of environmental factors [3–6]. FamilialTGF-b T869C (Leu 10Pro) gene polymorphism was determined
clustering of DMN has also been reported in variousby polymerase chain reaction (PCR).
populations [7, 8]. Both suggested that genetic factorsResults. Both groups of patients had similar baseline charac-
teristics, including blood pressure, diabetic control, and dura- could play a part in the pathogenesis of DMN. We have
tion of diabetes. Distribution of TGF- T869C (Leu 10Pro) previously reported the association of plasminogen acti-
genotype among the whole group is confined to Hardy Weinberg vator inhibitor (PAI-1) gene polymorphism with DMNequilibrium. The DMN group has higher frequency of TGF-b
among Chinese [9]. Recently, transforming growth fac-CC/CT genotypes than the DMN group [CC, CT, TT 
tor- (TGF-b) T869C (Leu 10Pro) gene polymorphism(DMN) 46, 45, 9 (%) vs. (DMN) 37, 37, 26 (%), P  0.05].
C allele frequency is also higher in the DMN group than is identified where the number of C allele correlates
DMN group (69% vs. 55%, P 0.05). The adjusted odds ratio positively with serum TGF- level [10]. Herein, we study
for TGF-b CC/CT vs. TT genotype to develop DMN is 3.8 (3.2 the relationship between TGF-b T869C (Leu 10Pro)to 4.4). Multivariate logistic regression analysis [hypertension,
gene polymorphism and DMN in Chinese.gender, age, duration of diabetes, hemoglobin (HbA1c), usage
of angiotensin-converting enzyme (ACE) inhibitor, and choles-
terol level] showed that TGF-b genotype (P  0.03) is an in-
METHODSdependent predictor for type 2 DMN. Among patients with
Patients
This is a case-control study performed in the PrinceKey words: type 2 diabetes mellitus, diabetic nephropathy, transform-
ing growth factor (TGF-) gene, gene polymorphisms. of Wales Hospital in Hong Kong. Type 2 diabetic pa-
tients (N  123) with more than 10-year history of dis-Received for publication July 23, 2002
ease were recruited (different patients from previousand in revised form September 12, 2002, and November 16, 2002
Accepted for publication December 17, 2002 study in reference [9]). Type 2 diabetes mellitus (DM)
is defined by the criteria of World Health Organization 2003 by the International Society of Nephrology
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(WHO) [11], together with absence of ketosis-prone All the reagents for PCR were purchased from Roche
Diagnostics (Roche, Switzerland). MspA1I was fromstate (absence of significant ketonuria and insulin treat-
ment started at least 1 year after diagnosis). Two well- New England Biolabs (USA). Genomic DNA was ex-
tracted from the white cells by standard technique. Thematched groups were identified for comparison. Group A
(N  65) consisted of type 2 diabetic patients with more primer sequences for codon 10 amplification were
5-TTC AAG ACC ACC CAC CTT CT-3 (sense) andthan 10 years history of diabetes without DMN (serum
creatinine120 mol/L and normoalbuminuric). Group B 5-TCG CGG GTG CTG TTG TAC A-3 (antisense).
A 30 L reaction mixture contained 1 PCR buffer, 1.5(N 58) consisted of diabetic patients with similar dura-
tion of disease who developed DMN. Patients were de- mmol/l MgCl2, 1 mol/L each primer, 0.2 mmol/L each
desoxynucleoside triphosphate (dNTP), 50 mL/L for-fined as having DMN if they had renal biopsy confirmed
diabetic glomerulosclerosis (DGS) (15% of group B), or mamide, 2.0 U Taq polymerase, and 25 ng genomic
DNA. The thermal cycler used was GeneAmp PCR Sys-presence of diabetic retinopathy or neuropathy at the
onset of renal disease when they presented with micro- tem 9600 (PE Applied Biosystems, USA). The thermal-
cycling conditions included an initial denaturing at 94	Cor macroalbuminuria, regardless of their renal function.
Patients with renal biopsy showing other types of glomer- for 5 minutes, followed by a 35 cycles of denaturing at
94	C for 30 seconds, annealing at 60	C for 30 seconds,ulonephritis, history of renal stones, single kidney, con-
trast- or drug-induced nephropathy or absence of retin- and extension at 72	C for 30 seconds. A final elongation
step of 72	C for 5 minutes was included.opathy at the onset of renal disease were excluded. Atypical
features like shrunken kidneys, significant microscopic To identify codon 10 restriction site polymorphism,
5 L PCR product (500 bp) was digested with 10.0 Uhematuria, or those with renal disease without diabetic
retinopathy were included only if biopsy confirmed DGS MspA1I in a 20 L reaction mixture which contained
1 reaction buffer and 100g/mL bovine serum albumin(comprised 15% of group B patients). Another 90 Chi-
nese healthy subjects (nondiabetic, nonhypertensive vol- (BSA) supplied by the manufacturer. The restriction cut-
ting mixture was incubated at 37	C overnight. The di-unteers) were recruited as healthy control.
During the visits, fasting blood samples were checked gested samples were then separated in 2% agarose gel
and visualized by ethidium bromide staining and ultra-for glucose, hemoglobin (HbA1c), and lipids. Arterial blood
pressure was measured after 5 minutes rest using a stan- violet transillumination. The genotypes for869 (codon
10) restriction site polymorphism were CC (Pro/Pro)dard sphygmomanometer. Hypertension was defined as
systolic pressure or diastolic blood pressure
140 mm Hg (273 bp), and CT (Pro/Leu) (273 bp and 285 bp) and
TT (Leu/Leu) (285 bp).or 90 mm Hg, respectively, or if the patient was on anti-
hypertensive drugs. Fundal examination was performed
Statistical analysisby ophthalmologist or physician and diabetic retinopathy
was defined as the presence of proliferative or back- By calculation, a sample size of 108 can achieve 80%
power to detect an effect size (W) of 0.26 (medium effect)ground diabetic retinopathy. About 60% to 70% of pa-
tients were assessed by ophthalmologist and the rest by using 2 degrees of freedom chi-square test with a sig-
nificance level (alpha) of 0.05. Results are expressed asphysician alone. HbA1c was measured by an automated
ion-exchange chromatographic method (Bio-Rad, Her- mean  SD for normally distributed data and median
(range) for skewed data. Statistical significance was testedcules, CA, USA) (reference range, 5.1% to 6.4%). Uri-
nary albumin concentrations were measured by immuno- using unpaired Student test and Mann-Whitney test as
appropriate. Comparisons between groups were performedturbidimetry [12]. Spot urinary albumin/creatinine ratio
(ACR) was measured on three occasions during a 6-week using the chi-square test. One-way analysis of variance
(ANOVA) test was used to compare continuous dataperiod. Normoalbuminuria was defined as ACR30 mg
albumin/g creatinine on at least two of the three occa- among patients with different TGF-bT869C (Leu 10Pro)
genotypes. Multivariate logistic regression with two-waysions. Microalbuminuria was defined as ACR of 30 to
300 mg albumin/g creatinine and macroalbuminuria as analysis was used for analysis of independent risk factor
for DMN. P value of 0.05 (two-tailed) was considered
300 mg albumin/g creatinine.
significant.
Determination of TGF- T869C (Leu 10Pro)
gene polymorphisms
RESULTS
TGF-b T869C (Leu 10Pro) gene polymorphism was
Characteristics of patient populationsdetermined by a restriction site polymorphism (RSP)
method as described by Lario et al [13]. A fragment of The baseline characteristics of both groups are shown
in Table 1. All group A patients (N 65, without DMN)the promoter region of the TGF-b gene was amplified by
polymerase chain reaction (PCR) and subsequently di- had normal renal function and normoalbuminuria. For
group B (N  58, with DMN), 59% had macroalbumin-gested with restriction enzymes (MspA1I).
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Table 1. Clinical and biochemical characteristics of Chinese type 2 shown in Table 3. Patients with DMN had increased
diabetic patients with or without diabetic nephropathy (DMN)
prevalence of TGF CC and CT genotype [CC, CT, TT
Group A Group B 46%, 45%, 9% (with DMN) vs. 37%, 37%, 26% (without
(without DMN) (with DMN) P value DMN), P  0.03]. The frequencies of C alleles were also
No. of patients 65 58 NS higher among those with DMN than those without [69%
Gender male:female 48:52 44:56 0.6
vs. 55%, P 0.04]. Risk remained unchanged after multi-Age 7011 7210 0.4
Duration of diabetes years 13.45.6 13.74.8 0.7 variate logistic regression analysis using (1) covariates,
Creatinine lmol/La 83 (46–122) 99 (49–404) 0.001 including gender, age, duration of diabetes, hypertension,
HbA1c % 7.71.2 7.51.3 0.4 cholesterol level, HbA1c, usage of ACE inhibitor, and theMean blood pressure mm Hg 9411 9813 0.3
Cholesterol mmol/L 5.030.93 5.060.95 0.9 presence of C allele; or (2) dependent factors, including
% with hypertension 81 89 0.2 presence of DMN (micro- or macroalbuminuria) for
% with macroalbuminuria 0 59 0.001
analysis (presence of TGF-b C allele, P  0.02 for back-% with retinopathy 31 39 0.5
% on ACE-inhibitor 58 74 0.07 ward method, P  0.02 for forward method, P  0.03
% on insulin 23 19 0.6 for one-step enter method). The adjusted odds ratio for
Abbreviations are: ACE, angiotensin-converting enzyme; HbA1c, hemoglo- presence of TGF- C allele for development of DMN
bin A1c. was 3.8 (confidence interval 3.2 to 4.4).a In median (range); others expressed as means  SD
Effect of TGF T869C (Leu 10Pro) gene
polymorphism on severity of DMNuria and 41% had microalbuminuria, while serum creati-
When only patients with DMN were included for anal-nine levels ranged from 49 to 404 mol/L. None of the
ysis (N  58), the CC/CT group also tended to havepatients required renal replacement therapy. Both
higher serum creatinine [100 (49 to 404) mol/L vs. 83groups had similar duration of DM, age, gender distribu-
(63 to 127) mol/L, P  0.03] and prevalence of macro-tion, HbA1c, retinopathy rates, and blood pressure con-
albuminuria (61% vs. 40%, P  0.6) than the TT group.trol. Compared with group A, higher prevalence of
However, the latter difference did not reach statisticalgroup B patients were treated with angiotensin-con-
significance.verting enzyme (ACE) inhibitor, though fell short of
statistical significance (74% vs. 58%) (P  0.07).
Effect of TGF T869C (Leu 10Pro) gene
Among patients with different TGF-b genotypes (Ta-
polymorphism on diabetic retinopathy
ble 2), baseline characteristics, including gender and age
The prevalence of diabetic retinopathy was similardistribution, metabolic and blood pressure control, prev-
among both groups, with and without DMN (31% toalence on insulin, and ACE inhibitor, were similar. How-
39%) (Table 1). There were no differences in the distri-ever, patients with TGF-bCC genotype had shorter dura-
bution of TGF-b T869C (Leu 10Pro) genotypes betweention of diabetes than the CT and TT genotype groups
patients with or without retinopathy [35%, 50%, 15%[(CC) 12  3 vs. (CT) 14  6 vs. (TT) 14  5 years,
(with retinopathy) vs. 45%, 35%, 20% (without retin-P 0.027]. The prevalence of DMN was however highest
opathy), P  0.3].among those with TGF-b CC and CT genotypes than
those with TT genotypes [(CC) 53% vs. (CT) 52% vs.
(TT) 23%, P  0.03]. TGF-b CC and CT groups also DISCUSSION
had worse renal function than TT group (P  0.001). TGF- is known to be a key regulator in extracellular
matrix molecule production (e.g., collagens, fibronectin,
Difference in distribution of TGF-b T869C and proteoglycans) [14]. Its over-expression is one of the
(Leu 10Pro) genotype among patients with most constant molecular features of pathologic tissue
and without DMN fibrosis leading to organ failure [15]. The onset of DMN
The values predicted by the assumption of Hardy- is characterized by renal hypertrophy, basement mem-
Weinberg equilibrium in the whole group of studied sub- brane thickening, and mesangial expansion [16]. Patho-
jects were similar to those observed [CC, CT, TT 41%, logic accumulation of mesangial extracellular matrix
41%, 18% (observed) vs. 38%, 47%, 14% (predicted), (ECM) is also known to be important in the progression
P  NS]. There is no differences in the TGF-b T869C of glomerulosclerosis [17]. Control of ECM deposition
(Leu 10Pro) genotypic distribution between diabetic is believed to be crucial in the development and progres-
subjects and healthy control (N  90) [(CC, CT, TT  sion of diabetic renal disease. Evidence implicating a
35%, 43%, 21% (control), P  NS], which shows that role of TGF- in pathogenesis of DMN is overwhelming
TGF-b gene polymorphism is not associated with DM. [18]. TGF- was expressed in proximal tubule epithelial
The genotypic distribution and allele frequencies of cells and renal interstitial fibroblasts while diabetic pa-
tients were found to have increased renal production ofthe TGF-b gene T869C (Leu 10Pro) polymorphism are
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Table 2. Characteristics and biochemical parameters of different transforming growth factor (TGF-) T869C (Leu 10Pro) genotypes
CC CT TT P value
No. 51 50 22
Age years 69.810.5 70.510.5 67.813.5 0.7
Gender male:female 42:58 45:55 60:40 0.4
Duration of diabetes years 124 146 145 0.027
HbA1c % 7.51.3 7.61.3 7.71.1 0.9
Cholesterol mmol/L 5.020.85 5.01.0 5.41.9 0.3
Mean blood pressure mm Hg 96.58.3 96.214.9 97.811.4 0.9
Creatinine lmol/La 89 (47–350) 93 (46–404) 81 (51–120) 0.001b
% with hypertension 88 87 84 0.5
% with retinopathy 32 41 23 0.4
% on ACE-I inhibitor 70 64 64 0.8
% on insulin 21 19 23 0.9
Abbreviations are: ACE, angiotensin-converting enzyme; HbA1c, hemoglobin A1c.
a In median (range); others expressed as means  SD
b P  0.001 CC vs. TT and CT vs. TT
Table 3. Distributions of transforming growth factor (TGF-) T869C (Leu 10Pro) genotypes and allele frequencies in Chinese type 2
diabetic patients with or without diabetic nephropathy (DMN)
Group A Group B
(without DMN) (with DMN)
(N  65) (N  58) P value
TGF T869C (Leu 10Pro) genotypes
CC 37% (24) 46% (27) 0.03
CT 37% (24) 45% (26)
TT 26% (17) 9% (5)
Allele frequency
C 55% 69% 0.04
T 45% 31%
TGF- protein [19]. Factors known to be associated with tion of -helices, whereas the cyclic structure of proline
results in breaks and kinks of the-helical portions of thedevelopment and progression of DMN, including hyper-
glycemia, increased intraglomerular pressure, mesangial peptide backbone. This results in dysfunction of intracel-
lular trafficking or export efficiency of the preprotein. Ex-cell stretch, activation of renin-angiotensin system, and
hypertension, have all been shown to induce TGF- pro- amination of circulating TGF- levels and TGF-b gene
polymorphism was not performed in our patients. How-duction in the kidney or in cultured mesangial or tubular
cells [19]. Administration of neutralizing TGF- anti- ever, serum TGF- concentration has been demon-
strated to be correlated positivity with the number ofbody suppressed renal TGF-, collagen, fibronectin pro-
duction, and renal hypertrophy in animal studies [20]. C alleles present in Japanese subjects [10] and CC/CT
genotype is shown to be associated with faster rate ofMoreover, intraglomerular TGF- mRNA was shown
to be positively correlated with the amount of type IV liver fibrosis in cirrhotic patients [25]. The TGF-b gene
polymorphism has also been found to be associated withcollagen in the mesangium, glomerular basement mem-
brane, and Bowman’s capsule in diabetic patients [21]. disease states such as osteoporosis and myocardial in-
farction where TGF- is believed to play an importantEvidence from these in vivo and in vitro studies indicate
that TGF- is a key mediator in diabetic renal disease. role [24–26]. Although TGF- is crucial in the pathogen-
esis of DMN and genetic control is likely to play a part,Preliminary studies based on twin analysis and the ob-
served large interindividual differences in TGF- mRNA research on the effect of TGF-b gene polymorphism on
DMN is, however, scanty. Pociot et al [27] showed nolevels among healthy individual subjects both suggested
that the concentration of serum TGF- is partly under association between TGF-b Thr236Ile and 713-8delC
gene polymorphisms with type 1 DMN in the Caucasian.genetic control [22, 23]. Recently, several TGF-b gene
polymorphisms have been identified [22, 23]. Among Akai et al [28] failed to detect an association between
TGF-b T29C gene polymorphism and the progression ofthese is the T→C polymorphism at exon 1, position869
of the TGF-b gene, resulting in the replacement of a leu- type 2 DMN in Japanese [28]. However, the latter study
is limited by the small sample size (N  40) and hencecine with proline at amino acid position 10 in the signal
sequence, which is believed to target newly synthesized a limited statistical power.
Our study is the first to show that TGF-b T869C (Leuproteins to the endoplasmic reticulum. Leucine possesses
a hydrophobic aliphatic side chain and favors the forma- 10Pro) gene polymorphism is associated with the risk
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7. Parving HH, Tarnow L, Rossing P: Genetics of diabetic nephrop-for development of type 2 DMN in Chinese, and proba-
athy. J Am Soc Nephrol 7:2509–2517, 1996
bly also with the severity of disease. This is consistent 8. Pettitt DJ, Saad MF, Bennett PH, et al: Familial predisposition
to renal disease in two generations of Pima Indians with type 2with the belief that TGF- is playing a vital role in DMN
diabetes mellitus. Diabetologia 33:438–443, 1990and that genetic factor also contributes significantly to
9. Wong TY, Poon P, Szeto CC, et al: Association of PAI-1 gene
the risk for DMN. In our study, patients with DMN polymorphism with type 2 diabetic nephropathy in Chinese. Kidney
Int 57:632–663, 2000(Table 1) were more likely to be treated with an ACE
10. Yamada Y, Miyauchi A, Goto J, et al: Association of a polymor-inhibitor, likely due to the tendency for the physician to phism of the transforming growth factor-1 gene with genetic sus-
prescribe an ACE inhibitor at the presence of DMN. ceptibility to osteoporosis in postmenopausal Japanese women.
J Bone Miner Res 13:1569–1576, 1998Nevertheless, usage of an ACE inhibitor is not an inde-
11. World Health Organization: Diabetes mellitus: Report of apendent predictor for DMN in multivariate analysis. WHO Study group (Technical report series 727) Geneva, World
Although retinopathy has been strongly correlated Health Organization, 1985, p 11
12. Cheung CK, Swaminathan R: Rapid economical immuno-turbidi-with DGS, discordance in risk for the two complications
metric method for albuminuria. Clin Chem 33:204–205, 1987
is not uncommon, and it has been suggested that the 13. Lario S, Inigo P, Campistol JM, et al: Restriction enzyme-based
method for transforming growth factor-1 genotyping: Nonisotopictwo complications show dissimilar genetic predisposition
detection of polymorphisms in codons 10 and 25 and the 5-flanking[29, 30]. We have previously found that in our popula-
region. Clin Chem 45:1290–1292, 1999
tion, 40.5% of patients with biopsy-proved DGS did not 14. Sharma K, Ziyadeh FN: The emerging role of transforming growth-
in kidney diseases. Am J Physiol 226:F829–F842, 1994have retinopathy, and 13.6% of diabetic patients with
15. Border WA, Noble NA: Transforming growth factor- in tissueretinopathy did not have DGS, but instead a nondiabetic fibrosis. N Engl J Med 331:1286–1292, 1994
nephropathy [31]. 16. Osterby R, Gall MA, Schmitz A: Glomerular structure and
function in proteinuric type 2 diabetic patients. Diabetologia 36:The high prevalence of nephropathy in Chinese type
1064–1070, 19932 diabetic patients has been a heavy burden to the health 17. Klahr S, Schreiner G, Ichikawa I: The progression of renal
care system in our society. Apart from glycemic and disease. N Engl J Med 318:1657–1666, 1988
18. Border WA, Yamamoto T, Noble NA: Transforming growth fac-blood pressure control, genetic factor also plays an im-
tor  in diabetic nephropathy. Diab Metab Rev 12:309–339, 1996portant role. We found that TGF-b T869C (Leu 10Pro) 19. Sharma K, Ziyadeh FN: Hyperglycemia and diabetic kidney dis-
genotype is associated with an increased risk and severity ease. The case for transforming growth factor- as a key medicator.
Diabetes 44:1139–1146, 1995for nephropathy in Chinese type 2 diabetic patients. Nev-
20. Sharma K, Jin Y, Guo J, et al: Neutralization of TGF- by anti-ertheless, due to the potential limitation of population TGF- antibody attenuates kidney hypertrophy and the enhanced
extracellular matrix gene expression in STZ-induced diabetic mice.admixture in a cross-sectional study, other study designs
Diabetes 45:522–530, 1996like affected sib-pair analysis and transmission disequi-
21. Iwano M, Kubo A, Nishino T, et al: Quantification of glomerular
librium test involving families with affected disease may TGF-1 mRNA in patients with diabetes mellitus. Kidney Int 49:
1120–1126, 1996be useful to confirm the findings.
22. Wood NAP, Thomson SC, Smith RM, et al: Identification of human
TGF-1 signal (leader) sequence polymorphisms by PCR-RFLP.
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